Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

MRD-driven strategies and novel immunotherapies for multiple myeloma

Myeloma Knowledge Exchange 2021 (MyKE Myeloma)

Published: 25 Oct 2021

Views: 1180

Rating:

Save

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

Prof Simon Harrison speaks to ecancer about MRD-driven strategies and novel immunotherapies for multiple myeloma.

He talks about his presentation at MyKE Myeloma 2021.

Initially, Prof Harrison talks about the MRD-driven strategies in NDMM.

He then explains some of the novel immunotherapies for multiple myelomas.

Prof Harrison concludes by discussing bispecific antibodies, CAR T therapies and ADCs.

Related Videos

The Vanessa Moss Prize: celebrating research into cancer health disparities

Dr Olubukola Ayodele - University Hospitals of Leicester NHS Trust, Leicester, UK

The Vanessa Moss Prize: celebrating research into cancer health disparities ( Dr Olubukola Ayodele - University Hospitals of Leicester NHS Trust, Leicester, UK )

The 5-year long-term outcomes of radiation technique for locally advanced NSCLC

Dr Stephen Chun - MD Anderson, Houston, USA

The 5-year long-term outcomes of radiation technique for locally advanced NSCLC ( Dr Stephen Chun - MD Anderson, Houston, USA )

OncoAlert Round Up for August 25th - 31st, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Latest in immunological technologies that can treat, control, and prevent cancer

Dr Jill O’Donnell-Tormey - Chief Executive Officer, Cancer Research Institute

Latest in immunological technologies that can treat, control, and prevent cancer ( Dr Jill O’Donnell-Tormey - Chief Executive Officer, Cancer Research Institute )

NSIA and Nigeria to improve treatment for Nigerians through the building of new cancer centres

Aminu Umar-Sadiq - MD & CEO, Nigeria Sovereign Investment Authority (NSIA)

NSIA and Nigeria to improve treatment for Nigerians through the building of new cancer centres ( Aminu Umar-Sadiq - MD & CEO, Nigeria Sovereign Investment Authority (NSIA) )

Choosing Wisely in pathology

Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in pathology ( Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer